Ignacio Casarini

3.2k total citations
10 papers, 78 citations indexed

About

Ignacio Casarini is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Ignacio Casarini has authored 10 papers receiving a total of 78 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 1 paper in Molecular Biology. Recurrent topics in Ignacio Casarini's work include Lung Cancer Treatments and Mutations (9 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Lung Cancer Research Studies (4 papers). Ignacio Casarini is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Lung Cancer Research Studies (4 papers). Ignacio Casarini collaborates with scholars based in Türkiye, Spain and Japan. Ignacio Casarini's co-authors include Mustafa Özgüroğlu, Manuel Cobo, Shun Lü, Suresh S. Ramalingam, Terufumi Kato, Toon van der Gronde, Rachel Hodge, Matilde Saggese, Corinne Faivre‐Finn and Fiona Hegi‐Johnson and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Journal of Thoracic Oncology.

In The Last Decade

Ignacio Casarini

9 papers receiving 76 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ignacio Casarini Türkiye 5 61 55 11 9 7 10 78
E. Felip Font Spain 6 77 1.3× 89 1.6× 9 0.8× 20 2.2× 9 1.3× 15 109
Linnea Fulton United States 5 64 1.0× 55 1.0× 20 1.8× 9 1.0× 18 2.6× 6 80
Siegfried Haas Germany 5 42 0.7× 52 0.9× 6 0.5× 6 0.7× 9 1.3× 17 68
Paul DeSouza Australia 3 29 0.5× 46 0.8× 18 1.6× 15 1.7× 5 0.7× 5 68
Adrienne Bettini Switzerland 4 61 1.0× 57 1.0× 11 1.0× 2 0.2× 4 0.6× 10 74
Spartak Valev Bulgaria 3 20 0.3× 47 0.9× 9 0.8× 9 1.0× 10 1.4× 6 69
B. Bermejo De Las Heras Spain 5 33 0.5× 53 1.0× 5 0.5× 5 0.6× 17 2.4× 19 68
Miranda Gogishvili United States 7 89 1.5× 109 2.0× 8 0.7× 22 2.4× 14 2.0× 22 127
Julie S. Deutsch United States 5 21 0.3× 26 0.5× 12 1.1× 8 0.9× 4 0.6× 9 43
Silvia Novello Italy 6 57 0.9× 61 1.1× 23 2.1× 4 0.4× 14 2.0× 13 81

Countries citing papers authored by Ignacio Casarini

Since Specialization
Citations

This map shows the geographic impact of Ignacio Casarini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ignacio Casarini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ignacio Casarini more than expected).

Fields of papers citing papers by Ignacio Casarini

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ignacio Casarini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ignacio Casarini. The network helps show where Ignacio Casarini may publish in the future.

Co-authorship network of co-authors of Ignacio Casarini

This figure shows the co-authorship network connecting the top 25 collaborators of Ignacio Casarini. A scholar is included among the top collaborators of Ignacio Casarini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ignacio Casarini. Ignacio Casarini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Casarini, Ignacio, Tibor Csőszi, Mehmet Alı Nahıt Şendur, et al.. (2025). Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial. Annals of Oncology. 36(7). 775–785. 4 indexed citations
2.
3.
Herbst, Roy S., Byoung Chul Cho, Mauricio Burotto, et al.. (2025). Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study. Journal of Thoracic Oncology. 20(9). 1302–1314.
4.
Ramalingam, Suresh S., Terufumi Kato, Xiaorong Dong, et al.. (2024). Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study.. Journal of Clinical Oncology. 42(17_suppl). LBA4–LBA4. 5 indexed citations
5.
6.
Herbst, Roy S., Byoung Chul Cho, Caicun Zhou, et al.. (2023). 64O Lenvatinib plus pembrolizumab, pemetrexed, and a platinum (len + pembro + chemo) as first-line therapy for metastatic non squamous non-small cell lung cancer (NSCLC): Phase III LEAP-006 study. Immuno-Oncology Technology. 20. 100536–100536. 3 indexed citations
7.
Kato, Terufumi, Ignacio Casarini, Manuel Cobo, et al.. (2023). Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives. Lung Cancer. 187. 107414–107414. 9 indexed citations
8.
Peled, Nir, Julien Mazières, Dariusz M. Kowalski, et al.. (2023). 121P MK-7684A (vibostolimab [vibo] plus pembrolizumab [pembro] coformulation) with/without docetaxel in metastatic NSCLC after platinum-chemotherapy (chemo) and immunotherapy. Immuno-Oncology Technology. 20. 100593–100593. 6 indexed citations
9.
Lü, Shun, Ignacio Casarini, Terufumi Kato, et al.. (2021). Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non–small-cell Lung Cancer: LAURA Trial in Progress. Clinical Lung Cancer. 22(4). 371–375. 43 indexed citations
10.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by E. Felip Font Breakdown of academic impact, for papers by Linnea Fulton Breakdown of academic impact, for papers by Siegfried Haas Breakdown of academic impact, for papers by Paul DeSouza Breakdown of academic impact, for papers by Adrienne Bettini Breakdown of academic impact, for papers by Spartak Valev Breakdown of academic impact, for papers by B. Bermejo De Las Heras Breakdown of academic impact, for papers by Miranda Gogishvili Breakdown of academic impact, for papers by Julie S. Deutsch Breakdown of academic impact, for papers by Silvia Novello
Rankless by CCL
2026